Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.33 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15082416 | 0.89 | RXFP1 (0.41) | RXFP1MAPTACHETP53PDE4A | |
| SCHEMBL2084462 | 0.86 | PTGS2 (0.41) | RXFP1MAPTPDE4APDE4BPDE4C | |
| SCHEMBL12936334 | 0.81 | HRH3 (0.39) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL12936333 | 0.80 | PDE4A (0.38) | MAPTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12936332 | 0.78 | DRD2 (0.37) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL12936363 | 0.78 | MAPT (0.49) | MAPTMEN1KMT2A | |
| SCHEMBL12936331 | 0.76 | DRD2 (0.40) | MAPTACHEPDE4APDE4BPDE4C | |
| SCHEMBL14448883 | 0.76 | PDE4A (0.44) | RXFP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12936336 | 0.76 | KMT2A (0.42) | MAPTTP53PDE4APDE4BPDE4C | |
| SCHEMBL14448848 | 0.74 | ALDH1A1 (0.40) | MAPTTP53PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420653-B2 | Pyrimidine compounds and their uses | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-04-16 | — | — | US | disclosed |
| US-7863446-B2 | Heterocycles | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2011-01-04 | — | — | US | disclosed |
| US-20100329998-A1 | NOVEL HETEROCYCLES | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2010-12-30 | — | — | US | disclosed |
| US-20080207606-A1 | Novel heterocycles | ORCHID RESEARCH LABORATORIES LIMITED. (IN) | 2008-08-28 | — | — | US | disclosed |
| US-20070167413-A1 | Novel heterocycles | ORCHID RESEARCH LABORATORIES LIMITED. (IN) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207606-A1 | Novel heterocycles | GPR4, UACA, PDE4A | RXFP1 725/4885MAPT 583/4885ACHE 821/4885 |
| US-20100329998-A1 | NOVEL HETEROCYCLES | UACA, GPR4, CASP4 | RXFP1 1048/4885MAPT 587/4885ACHE 836/4885 |
| US-20070167413-A1 | Novel heterocycles | MCL1, UACA, MYLK2 | RXFP1 540/4885MAPT 128/4885ACHE 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.